TRAIL/TNFSF10 Protein, Human (HEK293, His-Flag)

TRAIL Protein (TNFSF10), a member of the TNF superfamily, is a type II transmembrane protein. TRAIL Protein mainly interacts with TRAIL-R1 and TRAIL-R2, and induces apoptosis in tumor or infected cells. TRAIL Protein also binds with DR4, DR5, and OPG. TRAIL Protein can recruit FADD and further recruit and activates caspase-8 after binding to DR4 or DR5. Besides, TRAIL may also trigger nonapoptotic signaling through activating pro-inflammatory pathways^[1][2]. TRAIL protein is mainly expressed on surface of immune cells, such as cytotoxic T cells and natural killer (NK) cell^[1]. TRAIL/TNFSF10 Protein, Human (HEK293, His-Flag) is a recombinant human TRAIL (G118-G281) with N-terminal His and Flag tag, which is expressed in HEK293.

TRAIL Protein (TNFSF10), a member of the TNF superfamily, is a type II transmembrane protein. TRAIL Protein is expressed in various tissues, especially in the spleen, lung, and prostate. TRAIL protein is mainly expressed on surface of immune cells, such as cytotoxic T cells and natural killer (NK) cell. TRAIL proteins on NK and T cells is critical for controlling virus infections and tumor immune surveillance^[1][2].
Human TRAIL consists of cytoplasmic domain (M1-V17), helical domain (L18-F38), and extracellular domain (T39-G281). Human TRAIL Protein shares < 70% common aa identity with mouse and rat. Mouse TRAIL Protein shares 86.94% common aa identity with rat.
TRAIL Protein mainly interacts with two agonistic TRAIL receptors (TRAIL-R1 and TRAIL-R2) and induces apoptosis in tumor or infected cells. TRAIL Protein also binds with DR4, DR5, and OPG. When binding to DR4 or DR5, TRAIL Protein can recruit FADD and further recruit and activates caspase-8. Besides, TRAIL may also trigger nonapoptotic signaling through activating pro-inflammatory pathways, such as NF-κB, PI3K/Akt, and MAPK pathway^[1][2].
TRAIL induces apoptosis of tumor cells in a p53 independent manner. TRAIL-based therapies has high anti-tumor potential^[3].

TRAIL (human, 1 ng/mL-1 μg/mL, 24 h) reduces cell viability of HepG2 cells^[4].
TRAIL (human, 1-1 ng, 24 h) induces pathognomic features of asthma and stimulates the production of CCL2 in primary human bronchial epithelium cells^[5].

Human

HEK293

N-His;N-Flag

P50591 (G118-G281)

8743  [NCBI]

55-65 kDa

Greater than 95% as determined by Tris-Bis PAGE.

<1 EU/μg, determined by LAL method.

• [1]. Cardoso Alves L, et al. The multifaceted role of TRAIL signaling in cancer and immunity. FEBS J. 2021 Oct;288(19):5530-5554.  [Content Brief]

  [2]. Zhong HH, et al. TRAIL-based gene delivery and therapeutic strategies. Acta Pharmacol Sin. 2019 Nov;40(11):1373-1385.  [Content Brief]

  [3]. Snajdauf M, et al. The TRAIL in the Treatment of Human Cancer: An Update on Clinical Trials. Front Mol Biosci. 2021 Mar 10;8:628332.  [Content Brief]

  [4]. Ganten TM, et al. Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs. Clin Cancer Res. 2006 Apr 15;12(8):2640-6.  [Content Brief]

  [5]. Weckmann M, et al. Critical link between TRAIL and CCL20 for the activation of TH2 cells and the expression of allergic airway disease. Nat Med. 2007 Nov;13(11):1308-15.  [Content Brief]